June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Reduction of Aqueous Levels of VEGF After Sequential Intravitreal Injections of Aflibercept in Diabetic Macular Edema
Author Affiliations & Notes
  • Kumar Sambhav
    University of Florida , Jacksonville, Florida, United States
  • Bharani k Mynampati
    University of Florida , Jacksonville, Florida, United States
  • K V Chalam
    University of Florida , Jacksonville, Florida, United States
  • sandeep Grover
    University of Florida , Jacksonville, Florida, United States
  • Footnotes
    Commercial Relationships   Kumar Sambhav, None; Bharani k Mynampati, None; K V Chalam, None; sandeep Grover, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 942. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kumar Sambhav, Bharani k Mynampati, K V Chalam, sandeep Grover; Reduction of Aqueous Levels of VEGF After Sequential Intravitreal Injections of Aflibercept in Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):942.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To measure the aqueous levels of vascular endothelial growth factor (VEGF) after each intravitreal injection of aflibercept in patients with diabetic macular edema (DME).

Methods : 14 eyes of nine patients with non-proliferative diabetic retinopathy (NPDR) and center-involving DME were included in the study. All the patients had well controlled type 2 diabetes for more than 5 years. All these patients received a course of 3 intravitreal injections of an anti-VEGF agent, aflibercept, 4-6 weeks apart. At each visit, before the injection of intravitreal aflibercept 2mg/0.05 ml, 80-100 µl of aqueous was removed to balance the intraocular pressure. These samples were rapidly cooled on ice, centrifuged to remove cells, and immediately stored in a −80°C freezer. At the time of measurement, the aqueous samples were thawed at room temperature and VEGF levels (pg/ml) were measured using standard Luminex 100 IS fluoroanalyzer (Luminex Inc., Austin, TX, US) method. To ensure a proper assay, a known concentration of human recombinant VEGF was included in each run as a positive control.

Results : The aqueous VEGF level was measured before and after treatment with 2 doses of intravitreal aflibercept. GraphPad InStat v.3; (San Diego, California, USA) was used for statistical analyses. The mean, standard deviation (SD), and median were calculated for aqueous VEGF levels at baseline (1 month after the first injection), 1 month (1 month after the second injection) and 2 months (1 month after the third injection). Non parametric one-way ANOVA (Kruskal-Wallis) was used to compare the mean values of aqueous VEGF levels for each visit.
The mean baseline anti-VEGF levels were 47.26 pg/ml [median 26.2; range 6.8-140.8]. The mean anti-VEGF levels at 4-6 weeks visit were 8.05 pg/ml [median 5.5; range 2-18.8] and at 8-12 weeks visit were 5.07 pg/ml [median 4; range 1.48-10.4]. Kruskal-Wallis test results showed statistically significant decrease in VEGF levels on comparing baseline visit to 4-6 weeks follow up visit (p<0.0001) and 8-12 week follow up visit (p=0.0008).

Conclusions : Aqueous concentrations of VEGF in patients with non-proliferative diabetic retinopathy and diabetic macular edema significantly decreases after treatment with intravitreal aflibercept. In the future, the measurement of VEGF levels in aqueous at every visit can possibly be used as a guide to plan treatment at an individual level.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×